Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics Inc (NY: LCTX )

1.055 +0.035 (+3.43%)
Streaming Delayed Price Updated: 11:06 AM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 96,601
Open 1.040
Bid (Size) 1.050 (13)
Ask (Size) 1.060 (14)
Prev. Close 1.020
Today's Range 1.030 - 1.060
52wk Range 0.8372 - 1.560
Shares Outstanding 174,986,671
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at 2024 BIO International Convention
From Lineage Cell Therapeutics, Inc.
Via Business Wire

Performance

YTD
-3.21%
-3.21%
1 Month
+14.38%
+14.38%
3 Month
-4.09%
-4.09%
6 Month
+0.48%
+0.48%
1 Year
-22.43%
-22.43%

More News

Read More
Lineage Cell Therapeutics: Q4 Earnings Insights
Via Benzinga
A Preview Of Lineage Cell Therapeutics's Earnings
Via Benzinga
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Changes to Board of Directors
From Lineage Cell Therapeutics, Inc.
Via Business Wire
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 7, 2024
Via Benzinga
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.